Lack of association between matrix metalloproteinase-1 (MMP-1) promoter polymorphism and risk of renal cell carcinoma

International Braz J Urol

Volumn 33, Issue 5, 2007, Pages 622-629

  Piccoli, Michelly F ^a   Figueira, Marcia ^a   Andreoni, Cassio ^a   Marumo, Julio T ^b   Schor, Nestor ^a   Bellini, Maria Helena ^a,b  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b INSTITUTO DE PESQUISAS ENERGÉTICAS E NUCLEARES   (Brazil)

Author keywords

MMP 1; Polymorphism; Renal cell carcinoma

Indexed keywords

EID: 36549063793     PISSN: 16775538     EISSN: 16776119     Source Type: Journal    
DOI: 10.1590/S1677-55382007000500003     Document Type: Article

References (31)

1. Farber E: The multistep nature of cancer development. Cancer Res. 1984; 44: 4217-23.
2. Weinberg RA: Oncogenes, antioncogenes, and the molecular bases of multistep carcinogenesis. Cancer Res. 1989; 49: 3713-21.
3. Forget MA, Desrosiers RR, Beliveau R: Physiological roles of matrix metalloproteinases: implications for tumor growth and metastasis. Can J Physiol Pharmacol. 1999; 77: 465-80.
4. Ninomiya S, Niimi T, Shimizu S, Sato S, Achiwa H, Ito H, et al: Matrix metalloproteinase-1 polymorphism of promoter region in sarcoidosis and tuberculosis patients. Sarcoidosis Vasc Diffuse Lung Dis. 2004; 21: 19-24.
5. Massarotti M, Marchesoni A, Biondi ML, Marasini B: Polymorphism in the matrix metalloproteinase-1 promoter gene and severity of rheumatoid arthritis. J Rheumatol. 2002; 29: 2241; author reply 2242.
6. de Souza AP, Trevilatto PC, Scarel-Caminaga RM, Brito RB, Line SR: MMP-1 promoter polymorphism: association with chronic periodontitis severity in a Brazilian population. J Clin Periodontol. 2003; 30: 154-8.
7. Orbe J, Fernandez L, Rodriguez JA, Rabago G, Belzunce M, Monasterio A, et al.: Different expression of MMPs/ TIMP-1 in human atherosclerotic lesions. Relation to plaque features and vascular bed. Atherosclerosis. 2003; 170: 269-76.
8. Zhu Y, Spitz MR, Lei L, Mills GB, Wu X: A single nucleotide polymorphism in the matrix metalloproteinase-1 promoter enhances lung cancer susceptibility. Cancer Res. 2001; 61: 7825-9.
9. Hirata H, Naito K, Yoshihiro S, Matsuyama H, Suehiro Y, Hinoda Y. A single nucleotide polymorphism in the matrix metalloproteinase-1 promoter is associated with conventional renal cell carcinoma. Int J Cancer. 2003; 106: 372-4.
10. Rutter JL, Mitchell TI, Buttice G, Meyers J, Gusella JF, Ozelius LJ, et al.: A single nucleotide polymorphism in the matrix metalloproteinase-1 promoter creates an Ets binding site and augments transcription. Cancer Res. 1998; 58: 5321-5.
11. Matsumura S, Oue N, Kitadai Y, Chayarna K, Yoshida K, Yamaguchi Y, et al.: A single nucleotide polymorphism in the MMP-1 promoter is correlated with histological differentiation of gastric cancer. J Cancer Res Clin Oncol. 2004; 130: 259-65.
12. Wenham RM, Calingaert B, Ali S, McClean K, Whitaker R, Bentley R, et al.: Matrix metalloproteinase-1 gene promoter polymorphism and risk of ovarian cancer. J Soc Gynecol Investig. 2003; 10: 381-7.
13. Murray GI, Duncan ME, O'Neil P, Melvin WT, Fothergill JE: Matrix metalloproteinase-1 is associated with poor prognosis in colorectal cancer. Nat Med. 1996; 2: 461-2.
14. Ghilardi G, Biondi ML, Mangoni J, Leviti S, DeMonti M, Guagnellini E, et al.: Matrix metalloproteinase-1 promoter polymorphism 1G/2G is correlated with colorectal cancer invasiveness. Clin Cancer Res. 2001; 7: 2344-6.
15. Hashimoto T, Uchida K, Okayama N, Imate Y, Suehiro Y, Hamanaka Y, et al.: Association of matrix metalloproteinase (MMP)-1 promoter polymorphism with head and neck squamous cell carcinoma. Cancer Lett. 2004; 211: 19-24.
16. Lai HC, Chu CM, Lin YW, Chang CC, Nieh S, Yu MH, et al.: Matrix metalloproteinase 1 gene polymorphism as a prognostic predictor of invasive cervical cancer. Gynecol Oncol. 2005; 96: 314-9.
17. Tower GB, Coon CI, Brinckerhoff CE: The 2G single nucleotide polymorphism (SNP) in the MMP-1 promoter contributes to high levels of MMP-1 transcription in MCF-7/ADR breast cancer cells. Breast Cancer Res Treat. 2003; 82: 75-82.
18. Figlin RA: Renal cell carcinoma: management of advanced disease. J Urol. 1999; 161: 381-6; discussion 386-7.
19. Storkel S, Eble JN, Adlakha K, Amin M, Blute ML, Bostwick DG, et al.: Classification of renal cell carcinoma: Workgroup No. 1. Union Internationale Contre le Cancer (UICC) and the American Joint Committee on Cancer (AJCC). Cancer. 1997; 80: 987-9.
20. Fuhrman SA, Lasky LC, Limas C: Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol. 1982; 6: 655-63.
21. Uneyama C, Shibutani M, Masutomi N, Takagi H, Hirose M: Methacarn fixation for genomic DNA analysis in microdissected, paraffin-embedded tissue specimens. J Histochem Cytochem. 2002; 50: 1237-45.
22. Nascimento EM, Spinelli MO, Rodrigues CJ, Bozzini N: DNA extraction from paraffin material protocol in order to analyse microssatellites in uterine leiomyoma. J Bras Patol Med Lab. 2003; 39: 253-5.
23. Wiencke K, Louka AS, Spurkland A, Vatn M, Schrumpf E, Boberg KM, et al.: Association of matrix metalloproteinase-1 and -3 promoter polymorphisms with clinical subsets of Norwegian primary sclerosing cholangitis patients, J Hepatol. 2004; 41: 209-14.
24. Zhu Y, Spitz MR, Lei L, Mills GB, Wu X: A single nucleotide polymorphism in the matrix metalloproteinase-1 promoter enhances lung cancer susceptibility. Cancer Res. 2001; 61: 7825-9.
25. Nishioka Y, Kobayashi K, Sagae S, Ishioka S, Nishikawa A, Matsushima M, et al.: A single nucleotide polymorphism in the matrix metalloproteinase-1 promoter in endometrial carcinomas. Jpn J Cancer Res. 2000; 91: 612-5.
26. Ju W, Kang S, Kim JW, Park NH, Song YS, Kang SB, et al.: Promoter polymorphism in the matrix metalloproteinase-1 and risk of cervical cancer in Korean women. Cancer Lett. 2005; 217: 191-6.
27. Jemal A, Tiwari RC, Murray T, Ghafoor A, Samuels A, Ward E, et al.: Cancer statistics, 2004. CA Cancer J Clin. 2004; 54: 8-29.
28. Chow WH, Gridley G, Fraumeni JF Jr, Jarvholm B: Obesity, hypertension, and the risk of kidney cancer in men. N Engl J Med. 2000; 343: 1305-11.
29. Chow WH, Devesa SS, Warren JL, Fraumeni JF Jr: Rising incidence of renal cell cancer in the United States. JAMA. 1999; 281: 1628-31.
30. Mulders P, Bleumer I, Oosterwijk E: Tumor antigens and markers in renal cell carcinoma. Urol Clin North Am. 2003; 30: 455-65.
31. Folgueras AR, Pendas AM, Sanchez LM, Lopez-Otin C: Matrix metalloproteinases in cancer: from new functions to improved inhibition strategies. Int J Dev Biol. 2004; 48: 411-24.